Evidence map›Paper›PMID 41992617›Full record

ArticleACS applied materials & interfaces2026

Research on Therapeutic Strategy of Inhalable Cell Membrane-Coated Nanodelivery Complexes Mediating Nrf2 Pathway for Ameliorating Pulmonary Fibrosis.

Jiacheng Li, Hengbing Li, Xinyue Wang, Can Wang, Jiao Sun, Chenghao Qu, Hui Tian

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS applied materials & interfaces, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Jiacheng LiDepartment of Thoracic Surgery, Qilu Hospital of Shandong University, Jinan, Shandong 250012, China.ORCID 0009-0006-3385-8099
Hengbing LiThe First Clinical Medical College, Shandong University of Traditional Chinese Medicine, Jinan, Shandong 250355, China.
Xinyue WangSchool of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, Shandong 250012, China.
Can WangSchool of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, Shandong 250012, China.
Jiao SunDepartment of Rheumatology and Immunology, Shandong Provincial Third Hospital, Jinan, Shandong 250031, China.
Chenghao QuDepartment of Thoracic Surgery, Qilu Hospital of Shandong University, Jinan, Shandong 250012, China.ORCID 0000-0002-7325-4023
Hui TianDepartment of Thoracic Surgery, Qilu Hospital of Shandong University, Jinan, Shandong 250012, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Idiopathic pulmonary fibrosis is a progressive and fatal chronic lung disease with limited treatment options. Its pathogenesis is closely linked to aberrant activation of oxidative stress. The nuclear factor erythroid 2-related factor 2 (Nrf2), a central regulator of antioxidant responses, represents a promising therapeutic target for IPF. Additionally, M2 macrophage polarization and upregulation of the A

Indexed as

Cell MembraneNanoparticlesNF-E2-Related Factor 2Pulmonary FibrosisAdministration, InhalationAnimalsBleomycinHumansMacrophagesMiceMice, Inbred C57BLOxidative StressReactive Oxygen SpeciesRNA, Small InterferingSignal TransductionBleomycinNF-E2-Related Factor 2Reactive Oxygen SpeciesRNA, Small Interferingidiopathic pulmonary fibrosisinhalationmulberrinnanoparticlesNrf2

Identifiers

PMID41992617
PMCPMC13134637

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.